CTOs on the Move


 
TOLMAR is a northern Colorado based pharmaceutical research, development, manufacturing and commercial operations company. TOLMAR develops and manufacturers both proprietary and generic pharmaceutical products with specific focus in therapeutic areas of dental, dermatology, and oncology. TOLMAR provides our customers with a competitive and sustainable combination of product development and commercial services. Our strengths include a proven development, clinical, regulatory and manufacturing infrastructure with highly trained and experienced staff. Several of our marketed products are still in an early stage growth mode.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million
  • www.tolmar.com
  • 701 Centre Ave
    Fort Collins, CO USA 80526
  • Phone: 970.212.4500

Executives

Name Title Contact Details
Joe Miller
Vice President of Information Technology Profile

Similar Companies

Agenus

Agenus is an immuno-oncology company driven by innovation and speed. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients.

Cydan

Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential.

Pearl Therapeutics

Pearl Therapeutics is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sports Performance International

Sports Performance International is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aptinyx

Aptinyx Inc. (formerly Naurex Inc.) is a biopharmaceutical company focused on discovery and development of transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering compounds that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Aptinyx achieve this through a novel mechanism that modulates NMDA receptors, resulting in drugs that are both highly effective and well tolerated. This mechanism has applicability across a number of brain and nervous system disorders. Aptinyx is rapidly advancing promising drug candidates into clinical development for indications with high unmet medical need.